For Fiscal Year Ending Aug 31, 2019
Receive updates straight into your inbox
Agentix Biopharma is a biotechnology company focused on the development of synthetic agonists, inverse agonists and antagonists which modulate the endocannabinoid system (ECS). The ECS is a network of G-protein coupled receptors (GPCRs) that help regulate a variety of metabolic and neurotransmission functions. GPCRs are considered the largest family of proven therapeutic targets. To date there are over 134 drugs approved in the United States or the European Union which target GPCRs generating several billion dollars annually in revenues for pharmaceutical companies.
Agentix Biopharma has developed partnerships with leading academic and research institutions. Agentix Biopharma has exclusively licensed patented, synthetically-derived, small molecule therapeutic candidates targeting the endocannabinoid GPCRs (CB1/CB2) for the treatment of metabolic syndrome and peripheral inflammation. Agentix Biopharma is advancing these therapeutic product candidates in clinical trials.
 Sriram, K. & Insel, P., “G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?”, Molecular Pharmacology, 93:251–258, April 2018.
32932 Pacific Coast Highway Dana Point, CA 92629
West Coast Stock Transfer, Inc. 721 N. Vulcan Avenue #205 Encinitas, CA 92024 firstname.lastname@example.org
AGENTIX Biopharma Corp. (USA)
32932 Pacific Coast Highway
Dana Point, California 92629
AGENTIX Biopharma Corp. (Canada)
2275 Upper Middle Road East, #101
Oakville, Ontario L6H0C3
Website By: Symboliq Media